Ware

A new ovarian cancer vaccine

A new ovarian cancer vaccine



Scientists at Roswell Park Cancer Institute in Buffalo, New York, have reported that an experimental vaccine could help prevent ovarian cancer, reports WebMD Medical News. This vaccine is still in the testing stage and was designed to prevent relapse of ovarian cancer that has an extremely high rate (up to 70%).
This type of cancer is the most common of all cancers of the reproductive tract and a common cause of death in women because it is detected very late.
The vaccine improves the body's immunity, more precisely raises the blood level of certain cellular systems that play a role in immunity. So far, it has been tested on 18 women who have undergone chemotherapy. They were given 5 injections every 3 weeks. In total, they received about 15 injections.
The vaccine was effective for 6 months in some people and one year in others. No side effects were observed except pain at the injection site. So far, only the first test phase of the 3 has been reached, but the specialists hope that in the next 5 years the experiments will be completed.
Alina Sica
Editor
August 9, 2007